LISATA THERAP.INC.DL-001 Cash Flow Conversion Efficiency
LISATA THERAP.INC.DL-001 cash flow conversion efficiency. Based on the latest financial reports, LISATA THERAP.INC.DL-001 (8NE) has a cash flow conversion efficiency ratio of -0.332x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.65 Million ≈ $-3.10 Million USD) by net assets (€7.99 Million ≈ $9.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of LISATA THERAP.INC.DL-001 (2021–2025)
Cash flow conversion efficiency of LISATA THERAP.INC.DL-001 from 2021 to 2025. This chart illustrates how LISATA THERAP.INC.DL-001's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 8NE live share price for real-time trading data and today's change.
LISATA THERAP.INC.DL-001 Cash Flow Conversion Ratio Explained
LISATA THERAP.INC.DL-001 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
LISATA THERAP.INC.DL-001 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LISATA THERAP.INC.DL-001 ranked by their cash flow conversion efficiency. Also see LISATA THERAP.INC.DL-001 stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tay Ninh Cable Car Tour Co.
VN:TCT
|
-0.003x |
|
Lekoil Limited
F:L5K
|
0.029x |
|
Arrow Minerals Ltd
AU:AMD
|
-1.138x |
|
Dongyang S.Tec Co.Ltd
KQ:060380
|
0.012x |
|
Gladiator Resources Ltd
AU:GLA
|
-0.806x |
|
Golden Matrix Group Inc
NASDAQ:GMGI
|
0.102x |
|
General Engineering Public Company Limited
BK:GEL
|
0.044x |
|
M3-Brigade Acquisition V Corp. Warrant
NASDAQ:MBAVW
|
N/A |
Annual Cash Flow Conversion Efficiency for LISATA THERAP.INC.DL-001 (2021–2025)
The table below shows the annual cash flow conversion efficiency of LISATA THERAP.INC.DL-001 from 2021 to 2025. Review financial flexibility index of LISATA THERAP.INC.DL-001 to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €14.60 Million ≈ $17.07 Million |
€-15.95 Million ≈ $-18.65 Million |
-1.092x | -65.45% |
| 2024-12-31 | €29.32 Million ≈ $34.27 Million |
€-19.36 Million ≈ $-22.63 Million |
-0.660x | -57.85% |
| 2023-12-31 | €47.89 Million ≈ $55.99 Million |
€-20.03 Million ≈ $-23.42 Million |
-0.418x | -31.04% |
| 2022-12-31 | €66.32 Million ≈ $77.54 Million |
€-21.17 Million ≈ $-24.75 Million |
-0.319x | -32.01% |
| 2021-12-31 | €92.00 Million ≈ $107.56 Million |
€-22.25 Million ≈ $-26.01 Million |
-0.242x | -- |
About LISATA THERAP.INC.DL-001
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more